Subscribe
shutterstock_1953872293_marlon_trottmann
Marlon Trottmann / Shutterstock.com
9 March 2023Big PharmaMuireann Bolger

Don’t distort enablement law, Amgen tells SCOTUS

Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Amgen secures five-year ban on psoriasis drug copycat
20 April 2023   Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
Big Pharma
Deny Amgen’s ‘dangerous’ patent claims, Sanofi urges Supreme Court
7 February 2023   French pharma firm urges US court not to allow ‘monopoly’ over market | Enablement issue at centre of antibody patent case could have wide implications for pharma and life sciences industries.


Editor's picks

Astellas win strengthens blockbuster drug's European position
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

Editor's picks

Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Big Pharma
Amgen secures five-year ban on psoriasis drug copycat
20 April 2023   Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
Big Pharma
Deny Amgen’s ‘dangerous’ patent claims, Sanofi urges Supreme Court
7 February 2023   French pharma firm urges US court not to allow ‘monopoly’ over market | Enablement issue at centre of antibody patent case could have wide implications for pharma and life sciences industries.

More on this story

Big Pharma
Amgen secures five-year ban on psoriasis drug copycat
20 April 2023   Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
Big Pharma
Deny Amgen’s ‘dangerous’ patent claims, Sanofi urges Supreme Court
7 February 2023   French pharma firm urges US court not to allow ‘monopoly’ over market | Enablement issue at centre of antibody patent case could have wide implications for pharma and life sciences industries.

More features

The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
Why the Caribbean cannabis economy is ripe for IP protection
China filings push rise in patent applications in Ireland
Brain disorder medtech rivals butt heads at ITC
‘This is not a rescue deal’: How an acquisition fits London firm's plan
Alston & Bird partner with strong Japanese ties jumps to new firm
Chinese invisible braces maker hits back at infringement claims